A Phase 1/2 Study of DCC-3116 Plus Ripretinib for People with Advanced Gastrointestinal Stromal Tumor


Full Title

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies


Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.

Ripretinib is a standard treatment for GIST. It targets proteins that affect cancer growth, which may slow or stop cancer spread. DCC-3116 targets molecules that prevent tumor cells from recovering from the damage from other anti-cancer treatments, such as ripretinib. Both drugs are taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have GIST that has spread beyond its original location or to other parts of your body, even with treatment.
  • Have completed prior GIST treatment at least 2 weeks before getting the study treatment.
  • Not have had prior treatment with ripretinib.
  • Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
  • Be age 18 or older.


For more information and to see if you can join this study, please call Dr. Ping Chi’s office at 646-888-4166.




Phase I/II (phases 1 and 2 combined)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID